Sandoz Lines Up Higher-Strength Adalimumab In Europe
Filing For 100mg/ml Version Of Hyrimoz Biosimilar Rival To Humira Accepted By EMA
• By David Wallace
Could Europe soon become a three-player market for 100mg/ml adalimumab biosimilars? • Source: Shutterstock 
